Sarepta & BioMarin Settle Patent Litigation on Exon Skipping

Sarepta Therapeutics, Inc. SRPT and BioMarin Pharmaceutical Inc. BMRN, have settled their ongoing global patent litigation regarding the exclusive license on a patent pertaining to exon skipping technology used in Duchenne muscular dystrophy (DMD) therapies. BioMarin has licensed the global exclusive rights to its DMD patent estate for Exondys 51 and all future exon-skipping products to Sarepta Therapeutics.

Exondys 51 is a key drug for Sarepta and is marketed for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping.

A look at the company’s share price movement shows that, Sarepta has outperformed the Zacks categorized Medical-Biomed/Genetics industry so far this year. While the stock has rallied 23.5%, the broader industry witnessed a gain of 8.8%.

Per the agreement, Sarepta will make a one-time payment of $35 million to Biomarin plus unspecified regulatory and commercial milestone payments for exons 51, 45, 53, and on future exon-skipping products. Additionally, the company will pay BioMarin royalties for compounds skipping exons 51, 45, and 53, and possibly on future exon-skipping products.

BioMarin is entitled to receive 5% royalty on U.S. sales (through 2023) of Exondys 51 and both exons 45 and 53 skipping compounds, which use the exon skipping technology, and 8% royalty on European sales of the products (through Sep 2024).

BioMarin, however, has held back the right to convert the license to a co-exclusive right in case it decides to proceed with an exon-skipping therapy for DMD.

If Sarepta had not made the settlement with BioMarin, the latter could preclude Sarepta from commercializing Exondys 51 in several jurisdictions. Thus the settlement of patent litigation and the global license from Biomarin removes a major overhang for Sarepta.

Sarepta Therapeutics, Inc. Price and Consensus

 

Sarepta Therapeutics, Inc. Price and Consensus | Sarepta Therapeutics, Inc. Quote

Zacks Rank & Stocks to Consider

Sarepta currently carries a Zacks Rank #3 (Hold). Better-ranked health care stocks in the same space include Enzo Biochem, Inc. ENZ and Sanofi SNY. While Enzo Biochem sports a Zacks Rank #1 (Strong Buy), Sanofi holds a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Enzo Biochem’s loss per share estimates narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018, over the last 60 days. The company delivered positive earnings surprises in all the trailing four quarters, with an average beat of 55.83%. The share price of the company has increased 64.8% year to date.

Sanofi’s earnings per share estimates increased from $3.08 to $3.18 for 2017 and from $3.26 to $3.30 for 2018, over last 60 days. The company pulled off positive earnings surprises in three of the trailing four quarters, with an average beat of 5.10%. The share price of the company has increased 18% year to date.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Sanofi (SNY) : Free Stock Analysis Report
 
BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report
 
Enzo Biochem, Inc. (ENZ) : Free Stock Analysis Report
 
Sarepta Therapeutics, Inc. (SRPT) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research